Antibiotic Resistance Market Size (2024 - 2029)

Antibiotic Resistance Market Analysis

The Antibiotic Resistance Market size is estimated at USD 8.80 billion in 2024, and is expected to reach USD 11.5 billion by 2029, growing at a CAGR of 5.46% during the forecast period (2024-2029).

The key drivers of the market are the increasing burden of antibiotic-resistant infections across developed and developing regions and a shift in prescription patterns to newly launched therapies.

The increasing involvement of government and non-government bodies in developing novel therapies is anticipated to drive market growth. The high burden of antibiotic-resistant infections is a major concern globally. For instance, according to the CDC's data published in October 2022, more than 2.8 million antimicrobial-resistant infections occur each year in the United States, and more than 35,000 people die as a result of antibiotic resistance.

Moreover, in February 2023, the Australian government raised USD 6 million in funds for research into antimicrobial resistance and reducing the incidence of hospital infections. This grant opportunity was announced as part of the Medical Research Future Fund (MRFF) under the Global Health Initiative. Thus, such government initiatives are expected to boost the market's growth over the forecast period.

Some major companies operating in the AMR are adopting several strategies, such as collaboration and acquisition, along with various launches to strengthen their positions in the market. For instance, in January 2023, Alkem Laboratories launched an antibiotic, Zidavi, for multiple drug-resistant (MDR) infections. Moreover, in January 2023, Molbio Diagnostics launched Truenat MTB-INH to test the presence of isoniazid resistance in Mycobacterium tuberculosis in infection (MDR-TB). The test was validated by ICMR and approved by CDSCO, which can provide sample-to-test results in an hour.

The high burden of antibiotic resistance, the launch of new drugs for antibiotic-resistant infections, and initiatives taken by government are propelling the market growth. However, strict safety guidelines and the high cost of AMR therapeutics are expected to hinder the market's growth.

Antibiotic Resistance Industry Segmentation

As per the scope of the report, antibiotic resistance occurs when bacteria change in response to the use of these medicines. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria.

The antibiotic Resistance market is segmented by disease, pathogen, mechanism of action, drug class, distribution channel, and geography. By disease, the market is sub-segmented into Clostridioides difficile infection (CDI), complicated intra-abdominal infection (cIAI), acute bacterial skin and skin structure infections (ABSSSI), hospital-acquired and ventilator-associated bacterial pneumonias (HABP), complicated urinary tract infection (cUTI), community-acquired pneumonia (CABP), and bloodstream infection (BSI)). By pathogen, the market is sub-segmented into Acinetobacter baumannii, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, E. coli, and other pathogens. By drug class, the market is sub-segmented into Tetracyclines, Oxazolidinones, Cephalosporins, Lipoglycopeptides, Combination therapies, and other drug classes. By the mechanism of action, the market is sub-segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, and others. By distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is sub-segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the market sizes and forecasts in 17 countries across major regions. For each segment, the market sizing and forecasts were made on the basis of revenue (USD).